ResearchMoz

Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

GBI Research
Published Date » 2013-08-30
No. Of Pages » N/A
   
 GBI Research, the leading business intelligence provider, has released its latest research: Obesity Therapeutics to 2019 – Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs.  
   
 Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Etiology and Pathophysiology
2.2 Classification
2.3 Epidemiology
2.3.1 The US
2.3.2 Obesity in the Top Five European Markets
2.3.3 Japan
2.4 Comorbidities
2.4.1 Type 2 Diabetes
2.4.2 Hypertension
2.4.3 Dyslipidemia
2.4.4 Respiratory Problems
2.4.5 Osteoarthritis
2.4.6 Cancer Risk
2.5 Economic Burden
2.6 Current Therapy Options
2.6.1 Lifestyle and Behavioral Modifications
2.6.2 Bariatric Surgery
2.6.3 Pharmacotherapy
2.6.4 Treatment Algorithms and Prescription Habits
2.6.5 Method of Determining Treatment Effectiveness
2.7 Why Develop Therapeutic Anti-obesity Drugs?
2.8 GBI Research Report Guidance

3 Marketed Products
3.1 Amphetamine-like Drugs
3.1.1 Overview
3.1.2 Efficacy Profile
3.1.3 Safety Profile
3.2 Qsymia, Vivus, Inc.
3.2.1 Overview
3.2.2 Efficacy Profile
3.2.3 Safety Profile
3.2.4 Discussion
3.3 Orlistat
3.3.1 Overview
3.3.2 Efficacy Profile
3.3.3 Safety Profile
3.3.4 Discussion
3.4 Belviq, Arena Pharmaceuticals
3.4.1 Introduction
3.4.2 Efficacy Profile
3.4.3 Safety Profile
3.4.4 Discussion
3.5 Low Long-term Success Rate of Marketed Anti-Obesity Drugs
3.6 Discussion

4 Pipeline
4.1 Overview of Pipeline by Phase, Molecule Type and Molecular Target
4.2 Clinical Trial Duration and Size
4.2.1 Clinical Trial Duration
4.2.2 Clinical Trial Size
4.3 Clinical Trial Failure, Attrition Rate and Reasons for Clinical Trial Failure
4.4 Primary and Secondary Endpoints
4.5 Late-stage Drugs of the Developmental Pipeline
4.5.1 Contrave, Orexigen Therapeutics
4.5.2 Cametor, Norgine BV
4.5.3 Victoza, Novo Nordisk
4.5.4 Tesofensine (NeuroSearch)
4.6 Discussion

5 Market Forecasts
5.1 Global Market
5.2 The US
5.2.1 Epidemiology and Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Europe
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Japan
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Forecast
5.5 Discussion
5.6 Drivers and Barriers of the Anti-obesity Market
5.7 Obesity Market Drivers
5.7.1 Obesity is a Very Prevalent Disease with Large Potential Target Populations Globally
5.7.2 Recent Approval of Qsymia to Drive Market Growth Providing its Long-term Safety is Proved
5.7.3 Diversification of Molecular Targets
5.8 Obesity Market Barriers
5.8.1 Low Treatment Rate
5.8.2 Reimbursement Issues

6 Licensing and Co-Development Deals
6.1 Licensing Deals
6.1.1 EMD Serono Enters into Collaboration and Licensing Agreement with Theratechnologies
6.1.2 Amylin Pharma Enters into Licensing Agreement with Takeda Pharma
6.1.3 Palatin Technologies Extends License Agreement with AstraZeneca
6.1.4 Zealand Pharma Enters into Licensing and Collaboration Agreement with Boehringer
Ingelheim
6.2 Co-development Deals
6.2.1 Isis Enters into Collaboration Agreement with Ortho-McNeil
6.2.2 Orexigen Therapeutics Enters into Co-development Agreement with Takeda Pharma for
Contrave

7 Appendix
7.1 References
7.2 Abbreviations
7.3 All Pipeline Drugs by Phase
7.3.1 Discovery
7.3.2 Preclinical
7.3.3 Phase I
7.3.4 Phase II
7.3.5 Phase III
7.3.6 Pre-Registration
7.4 Market Forecasts to 2019
7.4.1 Global
7.4.2 The US
7.4.3 UK
7.4.4 France
7.4.5 Germany
7.4.6 Italy
7.4.7 Spain
7.4.8 Japan
7.5 Methodology
7.6 Secondary Research
7.7 Therapeutic Landscape
7.8 Epidemiology-Based Forecasting
7.9 Market Size by Geography
7.10 Pipeline Analysis
7.11 Contact Us
7.12 Disclaimer

List of Tables


Table 1: BMI Classifications
Table 2: Key Components of Pathways Thought to be Related to Obesity
Table 3: Treatment Options Dependent on BMI
Table 4: Obesity Therapeutics, Leading Brand Names of Phentermine
Table 5: Efficacy Results* for Qsymia at 52 Weeks
Table 6: Changes in Key Safety Parameters in Patients Treated with Qsymia
Table 7: Sales Data for Xenical ($m), 2008–2011
Table 8: Efficacy Results for Orlistat as an Initial and Maintenance Therapy
Table 9: Safety Results of Orlistat
Table 10: Efficacy Results for Belviq
Table 11: Placebo-adjusted Safety Results for Belviq
Table 12: Obesity Therapeutics Market, Global, Common Molecular Targets in the Obesity Pipeline
Table 13: Obesity Therapeutics Market, Global, Average Clinical Trial Size for the Most Common Modes of
Action Amongst Pipeline Drugs, 2006–2013
Table 14: Obesity Therapeutics Market, Global, Average Clinical Trial Duration for the Main Modes of
Action Amongst Pipeline Drugs, 2013
Table 15: Contrave, Phase III Clinical Trial Results
Table 16: Contrave, Efficacy Results, Phase III Clinical Trial
Table 17: Cametor, Efficacy Results of a Phase II Clinical Trial
Table 18: Cametor, Safety and Efficacy Results, Phase III Clinical Trial
Table 19: Victoza, Clinical Trial Results, Phase III Clinical Trial, 2009
Table 20: Victoza, Clinical Trial Results, Phase III Clinical Trial, 2009
Table 21: Victoza ,Safety and Efficacy Results, Phase III Clinical Trial, 2009
Table 22: Obesity Therapeutics Market, Europe, Current Prevalence Rate of the Population Which is
Obese or Overweight, 2012–2019
Table 23: Obesity Therapeutics Market: Global, Developmental Pipeline, Discovery Phase
Table 24: Obesity Therapeutics Market: Global, Developmental Pipeline, Preclinical Phase
Table 25: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase I
Table 26: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase II
Table 27: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase III
Table 28: Obesity Pharmacotherapy Market: Global, Developmental Pipeline, Pre-Registration
Table 29: Obesity Therapeutics Market, Global, Market Forecasts, 2012–2019
Table 30: Obesity Therapeutics Market, US, Market Forecasts, 2012–2019
Table 31: Obesity Therapeutics Market, UK, Market Forecasts, 2012–2019
Table 32: Obesity Therapeutics Market, France, Market Forecasts, 2012–2019
Table 33: Obesity Therapeutics Market, Germany, Market Forecasts, 2012–2019
Table 34: Obesity Therapeutics Market, Italy, Market Forecasts, 2012–2019
Table 35: Obesity Therapeutics Market, Spain, Market Forecasts, 2012–2019
Table 36: Obesity Therapeutics Market, Japan, Market Forecasts, 2012–2019

List of Figures


Figure 1: Obesity, Global, Prevalence (%), 1990–2010
Figure 2: Effects of Topiramate on Food Intake
Figure 3: Obesity Therapeutics Market, Obesity Drug Approvals and Market Removals
Figure 4: Obesity Therapeutics Market, Heat Map Comparing the Safety and Efficacy of Marketed Drugs
Figure 5: Obesity Therapeutics Market, Heat Map Comparing the Performance of Marketed Drugs in
Major Safety Parameters
Figure 6: Obesity Therapeutics Market, Global, Pipeline by Phase and Molecule Type and Molecular
Target
Figure 7: Obesity Therapeutics Market, Global, Clinical Trial Duration by Phase and Molecule Type, 2006–
2013
Figure 8: Obesity Therapeutics Market: Global, Clinical Trial Size by Phase and Molecule Type, 2006–2013
Figure 9: Obesity Therapeutics Market, Global, Clinical Trial Failure and Attrition Rates by Phase and
Molecule Type, 2006–2013
Figure 10: Obesity Therapeutics Market, Global, Clinical Trial Primary and Secondary Endpoints, 2006–2013
Figure 11: Heat Map Comparing the Safety and Efficacy of Marketed and Key Pipeline Drugs
Figure 12: Heat Map Comparing the Performance of Marketed and Key Pipeline Drugs in Major Safety
Parameters
Figure 13: Obesity Therapeutics Market, Global, Epidata and Market Forecasts, 2012–2019
Figure 14: Obesity Therapeutics Market, US, Epidata and Market Forecasts, 2012–2019
Figure 15: Obesity Therapeutics Market, Europe, Treatment Patterns, 2012–2019
Figure 16: Obesity Therapeutics Market, Europe, Annual Cost of Therapy, 2012–2019
Figure 17: Obesity Therapeutics Market, Europe, Market Forecasts, 2012–2019
Figure 18: Obesity Therapeutics Market, Japan, Epidata and Market Forecast, 2012–2019
Figure 19: Obesity Therapeutics Market, Global, Status, Value and Number of Licensing Deals, 2006–2013
Figure 20: Obesity Therapeutics Market, Global, Licensing Deals by Phase, Molecule Type and Value, 2006–
2013
Figure 21: Obesity Therapeutics Market, Global, Status, Value and Number of Co-development Deals,
2006–2011
Figure 22: Obesity Market, Global, GBI Research Market Sizing Model

Upcoming Reports:

Poland: sulphuric acid and oleum market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the sulphuric acid and oleum market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the sulphuric acid and oleum market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...
Base Oils-Lubes Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Base oils-lubes market is growing due to the increasing need for more sophisticated lubricants in the automotive industry. With the advancement in lubrication technology, base oils and lubricants market is expected to witness a rise in demand in the near future. Base oil quality and supply vary depending on the region and hence it is an important product in global trading. Growing economies are making huge investments in base oils-lubes market for developing higher grade base oils and lubricants to fulfill the growing demands from the industrial and automotive markets. ...
Greece: iron or steel structures market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the iron or steel structures market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the iron or steel structures market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

ARM-based Microcontrollers Launched by Toshiba
Jan 29, 2015  
Recently, Toshiba has added to its line two ARC Cortex M4F based microcontrollers of the series TX04. These two microcontrollers called TMPM475FDFG and TMPM470FDFG are able to operate at two non-brush DC motors simultaneously. These two microcontrollers are aimed to satisfy the demands of consumers for more efficient motors and add the vectoring technology to make sure a high-level...
Telefonica Deal Allows Sky to Venture into U.K. Mobile Market
Jan 29, 2015  
Sky Telecom Inc. on Thursday announced that beginning from 2016, the telecommunications company will be offering mobile services in the United Kingdom. This will be possible after the mobile virtual network operator (MVNO) deal with Spanish multinational telecommunications company Telefonica is finalized. Sky’s strategy so far has been to deliver premium content to its mobile...
Increasing LTE Subscribers Help SK Telecom Jump Q4 Net
Jan 29, 2015  
South Korea’s leading mobile operator SK Telecom Co. said on Thursday that its fourth quarterly earnings jumped owing to a surge in number of subscribers who switched to its speedier mobile internet connection. Another reason for this jump in earnings was due to an increase in sales from the business solution services division of SK Telecom. The net profit came to a total of...
Kuwait’s Zain Plans Potential Sale of Transmitter Towers
Jan 29, 2015  
Zain, a telecom operator in Kuwait has appointed a team of advisors to help analyze the prospective sale of the operator’s transmitter towers in a few of the eight markets where it has operations. The company issued a statement on Wednesday where the announcement was made. Zain has controlling stakes in numerous mobile companies in Iraq, Kuwait, South Sudan, Sudan, Jordan, and...
JCTC to Partner with Manufactures to train Students
Jan 29, 2015  
Chip Blankenship, CEO of GE Appliances announced his plan to form a partnership with Technical College and Jefferson Community to bridge the gap between skilled manufacturing labor and unmet demand in the industry. According to a report published by Kentucky Federation for Advanced Manufacturing Education, there are about 600,000 jobs that have to be filled in with skilled...